An interventional study of UV Light Treatment in Coronavirus, sponsored by Cedars-Sinai Medical Center. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-01-09.
Sponsored by Cedars-Sinai Medical Center · Not applicable, Interventional, and Treatment
This pilot study will assess the safety and effectiveness of UV light treatment in hospitalized patients with COVID-19.
This is a single center, open label, pilot study. 5 adult patients, aged over 18, who are confirmed positive with SARS-CoV-2 and are newly intubed, will receive UV light treatment to reduce SARS-CoV-2 viral load.
929 studies on the registry are indexed under Coronavirus Infections; 50 are open to participants now.
This study's enrollment of 5 is below the median of 107 across 541 interventional studies indexed under Coronavirus Infections.
Browse Coronavirus Infections studies →Cedars-Sinai Medical Center is the lead sponsor of 441 studies on the registry; 108 are open to participants now.
Of its 62 completed or terminated interventional studies of FDA-regulated products, 47 (76%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Mechanically ventilated patients who will receive UV Light therapy
Device: UV Light Treatment
UV light therapy administered while patient is mechanically ventilated
Negative Change in Viral Load
Change of viral load in upper airway in patients admitted to hospital for COVID-19
Time frame: 5 days
Change in Bacterial Load
Change of bacterial load in upper airway
Time frame: 5 days
Ventilated Associated Pneumonia
Percentage of patients developing ventilated pneumonia (VAP) within 30 days of treatment
Time frame: 1 month
Days to Extubation
Number of days patient is intubated with endotracheal tube or tracheostomy
Time frame: 1 month
Days to Discharge
Number of days patient is discharged from the hospital
Time frame: 1 month
Change in C-reactive Protein
Change in C-reactive protein from baseline to the end of the treatment
Time frame: 5 days
Change in the World Health Organization (WHO) Coronavirus Disease (COVID)-19 10-point Ordinal Severity Scale by 30 Days
The World Health Organization (WHO) COVID-19 10-point ordinal severity scale: 0 uninfected, No viral RNA detected 1. Asymptomatic; viral RNA detected 2. Ambulatory Mild disease: Symptomatic; independent 3. Ambulatory Mild disease: Symptomatic; assistance needed 4. Hospitalized: Moderate disease; no oxygen therapy 5. Hospitalized: Moderate disease; oxygen by mask or nasal prongs 6. Hospitalized: sever disease, Oxygen by non-invasive ventilation or high flow 7. Hospitalized: severe disease, intubation and mechanical ventilation, pO2/FiO2\>=150 or SpO2/FiO2\>=200 8. Hospitalized: severe disease, Mechanical ventilation pO2/FiO2\<150(SpO2/FiO2 \<200) or vasopressors 9. Hospitalized: severe disease, Mechanical ventilation pO2/FiO2\<150 and vasopressors, dialysis or extracorporeal membrane oxygenation 10. Death
Time frame: 1 month
Catheter Tip Assessment on the Last Day of Treatment
Assessment of total bacterial load on the UV catheter tip on the last day of treatment
Time frame: 5 days
| Milestone | Endotracheal UV Light |
|---|---|
| Started | 5 |
| Completed | 5 |
| Not completed | 0 |
Change of viral load in upper airway in patients admitted to hospital for COVID-19
| log10 copies/mL | Endotracheal UV Light |
|---|---|
| Negative Change in Viral Load | 3.2 (1.20 to 6.77) |
Change of bacterial load in upper airway
| Colony forming units/mL | Endotracheal UV Light |
|---|---|
| Change in Bacterial Load | 102000 ± 594000 |
Percentage of patients developing ventilated pneumonia (VAP) within 30 days of treatment
| Participants | Endotracheal UV Light |
|---|---|
| Ventilated Associated Pneumonia | 1 |
Number of days patient is intubated with endotracheal tube or tracheostomy
| days | Endotracheal UV Light |
|---|---|
| Days to Extubation | 20.75 (6 to 30) |
Number of days patient is discharged from the hospital
| days | Endotracheal UV Light |
|---|---|
| Days to Discharge | 27.25 (19 to 30) |
Change in C-reactive protein from baseline to the end of the treatment
| mg/L | Endotracheal UV Light |
|---|---|
| Change in C-reactive Protein | 95.00 ± 48.00 |
The World Health Organization (WHO) COVID-19 10-point ordinal severity scale: 0 uninfected, No viral RNA detected 1. Asymptomatic; viral RNA detected 2. Ambulatory Mild disease: Symptomatic; independent 3. Ambulatory Mild disease: Symptomatic; assistance needed 4. Hospitalized: Moderate disease; no oxygen therapy 5. Hospitalized: Moderate disease; oxygen by mask or nasal prongs 6. Hospitalized: sever disease, Oxygen by non-invasive ventilation or high flow 7. Hospitalized: severe disease, intubation and mechanical ventilation, pO2/FiO2\>=150 or SpO2/FiO2\>=200 8. Hospitalized: severe disease, Mechanical ventilation pO2/FiO2\<150(SpO2/FiO2 \<200) or vasopressors 9. Hospitalized: severe disease, Mechanical ventilation pO2/FiO2\<150 and vasopressors, dialysis or extracorporeal membrane oxygenation 10. Death
| Scores on a scale | Endotracheal UV Light |
|---|---|
| Change in the World Health Organization (WHO) Coronavirus Disease (COVID)-19 10-point Ordinal Severity Scale by 30 Days | 3.6 (-1 to 7) |
Assessment of total bacterial load on the UV catheter tip on the last day of treatment
No measurements were reported for this outcome.
Collected over Up to 30 following enrollment.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Endotracheal UV Light | 1/5 (20%) | 0/5 (0%) | 0/5 (0%) |
| Age, Categorical(Participants) | Endotracheal UV Light |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 4 |
| >=65 years | 1 |
| Sex: Female, Male(Participants) | Endotracheal UV Light |
|---|---|
| Female | 2 |
| Male | 3 |
| Ethnicity (NIH/OMB)(Participants) | Endotracheal UV Light |
|---|---|
| Hispanic or Latino | 3 |
| Not Hispanic or Latino | 2 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Endotracheal UV Light |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 1 |
| White | 4 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(participants) | Endotracheal UV Light |
|---|---|
| United States | 5 |
Documents are hosted by the registry — open the source record to download them.
Plan to share: No
This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Cedars-Sinai Medical Center